Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 321

European Association of Nuclear Medicine Conference

Posted by fidest press agency su lunedì, 14 ottobre 2019

SHINE Medical Technologies, LLC today announced the creation of a new division of the company — SHINE Therapeutics. The establishment of the division enhances the company’s ability to focus on filling critical future needs in the rapidly growing therapeutic isotope market, while continuing to leverage its radioisotope production expertise.
The company’s Therapeutics division will initially focus on the development and commercialization of lutetium-177, or Lu-177, a therapeutic isotope that is combined with a disease-specific targeting molecule to treat cancer. Targeting molecules deliver Lu-177 atoms to cancer sites throughout the body, where they directly irradiate cancer cells.
The first Lu-177-based targeted radiotherapy (for neuroendocrine tumors) reached the market in 2018. Many high-potential targeted molecules for the treatment of a range of other cancers with Lu-177 are currently under investigation. SHINE is also evaluating additional medical isotopes with therapeutic properties for future development.Katrina Pitas, a 10-year veteran of SHINE who served most recently as the company’s vice president of business development, has been appointed vice president and general manager of SHINE Therapeutics.In May, the company entered an agreement with the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague) that provides SHINE with a global, exclusive license to a novel separation technology that it will use to separate lutetium from enriched ytterbium targets. The technology will enable SHINE to produce non-carrier-added, high-specific-activity Lu-177.
SHINE is continuing its efforts to bring molybdenum-99, or Mo-99, to a global market experiencing shortages that directly affect patient care. Construction of the company’s first-of-its-kind isotope production facility in Janesville, Wis., where it will produce Mo-99 using the company’s patented technology, is underway and progressing well.

Rispondi

Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo di WordPress.com

Stai commentando usando il tuo account WordPress.com. Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

 
%d blogger hanno fatto clic su Mi Piace per questo: